63064-31-3

Usage

Uses

Used in Pharmaceutical Industry:
Toluene-4-sulfonic acid 2-cyclopropyl-ethyl ester is used as an intermediate for the synthesis of various pharmaceutical compounds, contributing to the development of new drugs and medications.
Used in Agrochemical Industry:
This chemical compound is also utilized as an intermediate in the production of agrochemical compounds, playing a role in the development of pesticides and other agricultural chemicals to improve crop protection and yield.
Used in Organic Synthesis:
Toluene-4-sulfonic acid 2-cyclopropyl-ethyl ester serves as a reagent in organic synthesis reactions, where it is employed to introduce the tosyl group, a crucial step in the synthesis of certain organic molecules.
Used as a Protecting Group in Organic Chemistry:
In organic chemistry, Toluene-4-sulfonic acid 2-cyclopropyl-ethyl ester is used as a protecting group for alcohols, which is essential for carrying out selective reactions and preserving the integrity of specific functional groups during complex organic synthesis processes.
It is important to handle Toluene-4-sulfonic acid 2-cyclopropyl-ethyl ester with care, as it can be hazardous if not used properly, due to its reactive nature and potential health risks.

Upstream product

• 2566-44-1 1-cyclopropylethanol 
• 98-59-9 p-toluenesulfonyl chloride 
• 104-15-4 toluene-4-sulfonic acid 

Downstream Products

• 62781-99-1 cyclopentyl formate 
• 116773-99-0 formate ester of 4-penten-2-ol 
• 1105690-47-8 N-benzyl-5-(4-(2-cyclopropylethoxy)-2-oxopyridin-1(2H)-yl)-3-methylthiophene-2-carboxamide 
• 5648-88-4 3-cyclopropylpropan-1-amine 
• 1275599-82-0 C₃₀H₃₅N₃O₆ 

Relevant academic research and scientific papers

Pyridopyril compound and medical application thereof

The invention relates to a pyridine ring compound and a medical application thereof as shown in a formula (I). The invention further relates to a preparation method of the compound. Use of a pharmaceutical composition and as FGFR4 inhibitor for the treatment of cancer.

3-amino nafoxidine-containing quinazoline ketone PARP (Poly Adenosine Diphosphate Ribose Polymerase)-1/2 inhibitor as well as preparation method, medicinal composition and application thereof

The invention discloses a novel 3-amino nafoxidine-containing quinazoline-2,4(1H, 3H)-diketone PARP-1/2 (Poly Adenosine Diphosphate Ribose Polymerase) inhibitor as well as a preparation method, a medicinal composition and application thereof. Specifically, the invention relates to a 3-amino nafoxidine-containing quinazoline-2,4(1H, 3H)-diketone derivative and a medicinal salt thereof of formula (I) as shown in the specification, a preparation method thereof, a composition with one or more such compounds, preparation of the compounds, and application thereof in preparing medicines for preventing and/or treating PARP-1/2 related diseases.

Containing piperazinone quinazoline ketone PARP - 1/2 inhibitor and its preparation method, pharmaceutical composition and use thereof (by machine translation)

The invention discloses a new class of containing piperazinone quinazoline - 2, 4 (1 H, 3 H) - dione PARP - 1/2 inhibitor, and its preparation and pharmaceutical composition and use. Specifically, the invention relates to the general formula I shown containing of the piperazinone quinazoline - 2, 4 (1 H, 3 H) - dione derivatives and their pharmaceutically acceptable salt, and its preparation method, comprising one or more of the compounds of the composition, and the compounds in the preparation, the prevention and/or treatment with PARP - 1/2 of a disease associated with the use of the medicament. (by machine translation)

6-HYDROXY-4-OXO-1,4-DIHYDROPYRIMIDINE-5-CARBOXAMIDES AS APJ AGONISTS

The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments.

Piperazine derivatives and their use as therapeutic agents

Compounds for treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the compounds are of formula (I): where x y, W, V, R 2 , R 3 , R 4 , R 5 , R 6 , R 6a , R 7 , R 7a , R 8 , R 8a , R 9 and R 9a are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.

INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES

Inhibitors of viral replication of formula (I), their process of preparation and their therapeutical uses. The present invention relates to compounds, their use in the treatment or the prevention of viral disorders, including HIV.

DNA-dependent protein kinase (DNA-PK) inhibitors: Structure-activity relationships for O-alkoxyphenylchromen-4-one probes of the ATP-binding domain

Introduction of an O-alkoxyphenyl substituent at the 8-position of the 2-morpholino-4H-chromen-4-one pharmacophore enabled regions of the ATP-binding site of DNA-dependent protein kinase (DNA-PK) to be probed further. Structure-activity relationships have been elucidated for inhibition of DNA-PK and PI3K (p110α), with N-(2-(cyclopropylmethoxy)-4-(2-morpholino-4-oxo-4H- chromen-8-yl)phenyl)-2-morpholinoacetamide 11a being identified as a potent and selective DNA-PK inhibitor (IC50 = 8 nM).

ORGANIC COMPOUNDS

The present invention provides heterocyclic derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed.

Regiospecific synthesis of novel 6-amino-5-hydroxypyridazin-3(2H)-ones

The synthesis of a novel class of 6-amino-5-hydroxypyridazin-3(2H)-ones (3-oxo-2,3-dihydropyridazines) is described. These compounds also contain an ethoxycarbonyl moiety at the 4-position of the pyridazinone ring. They are prepared in good to moderate yi

Pyridine Derivatives For Inhibiting Human Stearoyl-Coa-Desaturase

Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I) where x, y, G, J, K, L, M, W, V, R2, R3, R4, R5, R5a,